Abstract
Purpose
Patients receiving high-dose I-131 to treat differentiated thyroid cancer are isolated from visitors to limit radiation exposure to reasonable levels. The appropriate isolation time is unclear and has not been reported in Korea. The purpose of this study was to estimate the isolation time and investigate the possibility of earlier release from isolation.
Methods
This study was a retrospective analysis of data from 71 patients (10 men and 61 women; mean age, 49 ± 11.1 y) who received 3.7 GBq (47 patients), 5.55 GBq (23 patients), or 7.4 GBq (1 patient) of I-131 between January 2008 and December 2008. The radiation dose was measured with a fixed probe placed inside the isolation room. The total estimated dose equivalent (TEDE) to family members, the time required for the external dose rate to become <0.07 mSv/h, and the time required for whole-body retention to become <1.2 GBq were calculated.
Results
By the TEDE criterion (<5 mSv), 70 of 71 patients (98.6%) could have been released without isolation. By the external dose rate criterion, 10 of 71 (14.1%) and 60 of 71 patients (84.5%) could have been released without isolation and within 24 h, respectively. With whole-body retention criterion, 19 of 71 (26.8%) and 48 of 71 patients (67.6%) could have been released within 24 h and within 48 h, respectively.
Conclusions
Appropriate release times were estimated and compared using different criteria. Most patients could have been released without isolation or within 24 h of radiation treatment.
Similar content being viewed by others
References
US Nuclear Regulatory Commission (1997) Release of patients administered radioactive materials. Regulatory guide 8.39. United States Nuclear Regulatory Commission, Washington DC
Choi YJ, Park YL, Koh JH (2008) Prevalence of thyroid cancer at a medical screening center: pathological features of screen-detected thyroid carcinomas. Yonsei Med J 49:748–756
Kang HW, No JH, Chung JH, Min YK, Lee MS, Lee MK et al (2004) Prevalence, clinical and ultrasonographic characteristics of thyroid incidentalomas. Thyroid 14:29–33
Park SG (2008) Effective half-life of I-131 in patients with differentiated thyroid cancer. Nucl Med Mol Imaging 42:464–468
Park HM, Jang JW, Yang HC, Kim YG (2007) Outpatient radioablation therapy for thyroid cancer patients with minimal radiation exposure to the family members. Nucl Med Mol Imaging 41:218–225
Venencia CD, Germanier AG, Bustos SR, Giovannini AA, Wyse EP (2002) Hospital discharge of patients with thyroid carcinoma treated with 131I. J Nucl Med 43:61–65
Barrington SF, Kettle AG, O’Doherty MJ, Wells CP, Somer EJR, Coakley AJ (1996) Radiation dose rates from patients receiving iodine-131 therapy for carcinoma of the thyroid. Eur J Nucl Med 23:123–130
Pant GS, Sharma SK, Bal CS, Rakesh K, Rath GK (2006) Radiation dose to family member of hyperthyroidism and thyroid cancer patients treated with 131I. Radiat Prot Dosim 118:22–27
Rutar FJ, Augustine SC, Colcher D, Siegel JA, Jacobson DA, Tempero MA et al (2001) Outpatient treatment with (131)I-anti-B1 antibody: radiation exposure to family members. J Nucl Med 42:907–915
Remy H, Borget I, Leboullex S, Guilbert N, Lavielle F, Garsi J et al (2008) 131I effective half-life and dosimetry in thyroid cancer patients. J Nucl Med 49:1445–1450
Pacilio M, Bianciardi L, Panichelli V, Argiro G, Ciprani C (2005) Management of 131I therapy for thyroid cancer. Nucl Med Commun 26:623–631
Rosario PW, Borges MA, Purish S (2008) Preparation with recombinant human thyroid-stimulation hormone for thyroid remnant ablation with 131I is associated with lowered radiotoxicity. J Nucl Med 49:1776–1782
Matovic MD, Jancovic SM, Jeremic M, Tasic Z, Vlajkovic M (2009) Unexpected effect of furosemide on radioiodine urinary excretion in patients with differentiated thyroid carcinoma treated with iodine 131. Thyroid 19:843–848
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lee, J.H., Park, S.G. Estimation of the Release Time from Isolation for Patients with Differentiated Thyroid Cancer Treated with High-dose I-131. Nucl Med Mol Imaging 44, 241–245 (2010). https://doi.org/10.1007/s13139-010-0041-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13139-010-0041-0